BioSpace News Archive

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday, February 10, 2020, at 9:00 a.m. Eastern time.

Frazier Healthcare Partners announced that Tanya Hayes, a human capital expert with deep experience building infrastructure to scale middle-market companies, has joined the Growth Buyout team as an Executive Partner.

The SPIE-Glebov UCF graduate student scholarship is part of a $2.5 million SPIE education funding initiative for optics and photonics

Crown Bioscience announced the presentation of new NAFLD/NASH data with Yale School of Medicine.

Feb. 4, 2020 13:30 UTC SAN DIEGO--( BUSINESS WIRE )-- Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is scheduled to participate in the BIO CEO & Investor Conference at the New York Marriott Marquis in New York on Feb 10th-11th.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that more mature interim TACTI-002 clinical data will be presented at the 34th German Cancer Congress taking place in Berlin from 19th to 22nd of February 2020.

Inato, a platform that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, announced it has raised a $14 million Series A round of venture capital financing.

SIRION Biotech GmbH and InProTher Aps announced a broad licensing agreement which includes coverage of SIRION’s adenovirus technologies to cancer vaccines encoding Endogenous Retrovirus -derived antigens for active immunotherapy.